Axial Spondyloarthritis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis
The purpose of this trial is to demonstrate the clinical efficacy of GR1501 at week 16; and to demonstrate safety and tolerability of GR1501 compared to placebo in patients with Radiographic Axial Spondyloarthritis at week 16 and long term safety up to Week 48。 The main question it aims to answer is whether GR1501 injection was superior to placebo in the proportion of subjects with ASAS20 response at week 16 in patients with Radiographic Axial Spondyloarthritis.
This is a randomized, double-blind, placebo-controlled, multicenter clinical study to evaluate the efficacy and safety of GR1501 injection in Radiographic Axial Spondyloarthritis, as well as a confirmatory clinical trial of immunogenicity. This clinical trial was divided into four stages, namely screening period (W-4~W0), core treatment period (W0~W16), maintenance treatment period (W16~W32), and follow-up period (W32~W48). target population： radiographic axial spondyloarthritis who had a inadequate response to NSAIDs or have a history of intolerance to NSAIDs. primary outcome measure:percentage of participants achieving an ASAS20 response in week 16. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05031767 -
Remote Monitoring of Axial Spondyloarthritis
|
N/A | |
| Completed |
NCT05162937 -
to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis
|
Phase 2 | |
| Completed |
NCT03622658 -
Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
|
Phase 2 | |
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Terminated |
NCT02437162 -
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
|
Phase 3 | |
| Enrolling by invitation |
NCT06072859 -
The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)
|
N/A | |
| Completed |
NCT02552212 -
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
|
Phase 3 | |
| Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Terminated |
NCT02897115 -
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
|
Phase 4 | |
| Completed |
NCT05019547 -
The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
|
||
| Recruiting |
NCT03738956 -
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
|
Phase 2/Phase 3 | |
| Enrolling by invitation |
NCT02962479 -
Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?
|
N/A | |
| Completed |
NCT04485078 -
Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
|
||
| Recruiting |
NCT05812157 -
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
|
N/A | |
| Completed |
NCT03039088 -
PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
|
||
| Completed |
NCT04368494 -
Exercise Therapy in Patients With Axial Spondyloarthritis
|
N/A | |
| Completed |
NCT03270501 -
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
|
Phase 3 | |
| Completed |
NCT03043846 -
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
|